糖基化终产物对人肾小球系膜细胞结缔组织生长因子及纤维连接蛋白基因表达的影响

目的：探讨体外培养条件下糖基化终产物（AGEs）对人肾小球系膜细胞结缔组织生长因子（CTGF）及纤维连接蛋白（FN）基因表达的影响。方法：用不同浓度体外制备的AGEs干预系膜细胞及同一浓度的AGEs干预细胞不同时间。应用RT-PCR检测细胞中CTGF和FN的mRNA水平。结果：随着AGEs干预浓度的增加或干预时间的延长，系膜细胞CTGF和FNmRNA水平与对照组相比显著上升。结论：AGEs可导致人肾小球系膜细胞CTGF和FNmRNA的表达增加，在糖尿病肾病的发生、发展中起一定作用。     

罗格列酮抑制糖基化终产物诱导大鼠血管平滑肌细胞钙化机制

目的探讨罗格列酮抑制糖基化终产物(AGEs)诱导大鼠血管平滑肌细胞(VSMCs)钙化的可能机制。方法在含10 mmol·L~(-1)β-甘油磷酸培养液中加入200 mg·L~(-1)的AGEs及不同浓度(10~(-7)～10~(-5)mol·L~(-1))的罗格列酮体外培养VSMCs,采用甲-酚酞络合酮方法测定细胞钙含量,real time-PCR检测肿瘤坏死因子α(Tnf-α)、白细胞介素6(Il-6)及糖基化终产物受体(Rage)mRNA表达,Western blotting检测Rage蛋白表达,ELISA法检测细胞上清Tnf-α、Il-6水平。结果 AGEs可使VSMCs钙含量增加,Tnf-α、Il-6及Rage mRNA和蛋白表达增加(P<0.01);罗格列酮组均可降低VSMCs细胞层钙含量,抑制上述影响(P<0.05)。结论罗格列酮可能通过抑制VSMCs Rage表达,降低Tnf-α、Il-6表达和分泌,减轻AGEs诱导的VSMCs钙化。     

罗格列酮抑制糖基化终产物诱导心肌成纤维细胞增殖和结缔组织生长因子及Smad的表达

Objective To investigate the effects of rosiglitazone on the proliferation,connective tissue growth factor and Smad expression in cultured cardiac fibroblasts induced by advanced glycosylation end-products (AGEs).Methods After being treated with various amounts of rosiglitazone,the cultured neonatal rat cardiac fibroblasts were incubated with AGEs.The status of cardiac fibroblasts proliferation and cell cycle were detected by 3-(4,5-dimethyhhiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTI) assay and flow cytometry.Furthermore,ELISA technique was applied to identify the level of TGF-β1.The protein expressions of CTGF and Smad in cardiac fibroblasts of neonatal SD rats were detected with Western blotting.Results The exposure of cardiac fibroblasts to AGEs at doses of 0-200 mg/L induced a dose-dependent increase in cell proliferation.At the concentration of rosiglitazooe (0.1,1,and 10 μmol/L),the cell proliferation was reduced compared with 200 mg/L AGEs group by O.823±0.072,0.785±0.060,0.601±0.081 vs 0.981±0.049,respectively (P < 0.05).The increased levels of TGF-β1 in supematants of cultured cardiac fibroblasts stimulated by AGEs were inhibited by rosiglitazone at the concentrations of 0.1,1,10μmol/L by 257.77±9.09,230.29±6.56,200.84±10.26 vs 300.68±8.56,respectively (vs 200 mg/L AGEs,P<0.01).Western blot indicated that pretreatment with rosiglitazone (0.1,1,and 10 μmol/L) inhibited CTGF protein production in a dose-dependent by 0.769±0.108,0.590±0.095,0.534±0.115 vs 1.021±0.113,respectively (vs 200 mg/L AGEs,P<0.01).It was also demonstrated that pretreatment with rosiglitazone (1 and 10 μmol/L) inhibited Smad2 protein production by 0.424±0.059,0.396±O.080 vs 0.572±0.073,respectively (vs 200 mg/L AGEs,P < 0.05 or P < 0.01).Meanwhile pretreatment with rosiglitazone (1 and 10 μmol/L) inhibited Smad4 protein production by 0.580±0.063,0.556±0.051 vs 0.672±0.059,respectively (vs 200 mg/L AGEs,P < 0.05 or P < 0.01).Conclusions The findings suggest that AGEs promote the proliferation of cardiac fibroblasts and stimulate the protein production of Smad and CTGF of cardiac fibroblasts.Rosiglitazone inhibits the above reaction.These results indicate that CTGF/Smad pathway may play an important role in the protective effect of rosiglitazone on myocardial fibrosis.     

超声联合一氧化氮微泡对大鼠心肌组织的生物学效应

目的:本研究旨在探讨超声联合一氧化氮(NO)微泡的作用对大鼠心肌组织局部基质衍生因子-1(SDF-1)的影响,及其对心肌组织作用的安全性?方法:将32只SPF级SD雄性大鼠随机分为4组,每组8只?第1?2?3组分别经尾静脉输入1 ml的NO微泡?普通脂质微泡以及PBS,并采用频率为1 MHz?强度为1 W/cm2的超声辐照大鼠心前区,辐照时间为10 min;第4组为空白对照组?4 h后每组处死4只大鼠,留取心肌组织进行HE染色,观察局部的炎症反应情况;同时留取血清标本用于检测肌酸激酶(CK),乳酸脱氢酶(LDH)和肌钙蛋白I(TnI)的含量?1周后处死剩余大鼠,取心肌组织进行RT-PCR和Western blot分别检测SDF-1的基因及蛋白相对表达量?结果:辐照4 h后留取心肌组织行HE染色显示各组均可见少量炎性细胞浸润,组间没有明显差异;血清学指标检测显示,第1组与第2组血清CK和LDH高于第3组和第4组,且差异有统计学意义(P < 0.05);第1组血清TnI低于第2组,但高于第3组和第4组,且差异有统计学意义(P < 0.05);辐照1周后留取的心肌组织行RT-PCR和Western blot分析结果均显示第1组SDF-1相对表达量最多,各组间进行两两比较,差异均有统计学意义(P < 0.05)?结论:超声联合NO微泡辐照大鼠心肌组织,与内含全氟显气体的普通脂质微泡一样,对心肌组织无明显破坏;但能使大鼠心肌组织SDF-1表达增加,其程度高于应用超声联合普通脂质微泡,因此,NO微泡应用于干细胞归巢将优于目前普通脂质微泡?     

江苏省医学会微循环专科分会2008年学术会议纪要

由江苏省医学会微循环专科分会主办、东南大学附属中大医院协办的江苏省医学会微循环医学2008年学术会议，于5月16日～18日在美丽的六朝古都南京顺利召开。     

羧甲基赖氨酸的研究进展

晚期糖基化终末产物(AGEs)是蛋白质、脂质或核酸等大分子物质的非酶糖基化产物。其在体内有多种不同的存在形式,研究最多的是羧甲基赖氨酸(CML),它是AGEs的主要抗原表位,体内分布广泛,在糖尿病并发症等病变和衰老的发生、发展中有重要作用。     

罗格列酮抑制糖基化终产物诱导心肌成纤维细胞增殖和结缔组织生长因子及Smad的表达

目的 探讨糖基化终产物(AGE)对培养乳鼠心肌成纤维细胞增殖、结缔组织生长因子(CTGF)和Smad2、Smad4蛋白表达的影响及罗格列酮的干预作用.方法 采用胰酶消化法和差速贴壁分离法获取心肌成纤维细胞,应用MTT法、流式细胞仪法分别观察不同浓度AGE及罗格列酮对心肌成纤维细胞的细胞增殖、细胞周期的影响,ELISA方法 检测细胞培养上清中TGF-β1水平,Westem印迹技术检测CTGF及Smad2、Smad4蛋白质表达.结果 在一定浓度范围内,AGE干预心肌成纤维细胞,随浓度的增加,细胞增殖更加显著,TGF-β1分泌增加,CTGF蛋白表达增加.罗格列酮(0.1、1、10μmoVL)干预后,随浓度的增加,抑制心肌成纤维细胞增殖(分别为0.823±0.072、0.785±0.060、0.601±0.081对0.981±0.049,P<0.05)、抑制心肌成纤维细胞分泌TGF-β1(分别为257.77±9.09、230.29±6.56、200.84±10.26对300,68±8.56,P<0.01)、抑制CTGF蛋白表达的作用都更加显著(分别为0.769±O.108、0.590±0.095、0.534±0.115对1.021±0.113,P<0.01).罗格列酮(1和10μmol/L)干预后可显著减少AGE诱导的Smad2的蛋白表达(分别为0.424±0.059对0.572±0.073,P<0.05;0.396±0.080对0.572±0.073,P<0.01),同时可显著减少AGE诱导的Smad4的蛋白表达(分别为0.580±0.063对0.672±0.059,P<0.05;0.556±0.051对0.672±0.059,P<0.01).结论 AGE刺激心肌成纤维细胞增殖及分泌TGF-β1,同时诱导CTGF、Smad2及Smad4蛋白表达,罗格列酮在一定程度上抑制AGE上述作用,表明罗格列酮抑制心肌成纤维细胞增殖的效应与CTGF/Smad通路密切相关.     

烟酸对C57BL/6J小鼠脂肪组织、血脂和主动脉粥样硬化的影响

目的 以C57BL/6J小鼠为载体,以烟酸为干预药物,探索脂肪组织、血脂和主动脉粥样硬化三者间的潜在关系.方法 将28只雄性C57BL/6J小鼠随机分为对照组(n=8)、模型组(n=10)和烟酸干预组(n=10),分别给予普通饲料、高胆固醇饲料、高胆固醇饲料+1%烟酸(w/w)处理.14周后酶法和免疫比浊法检测血清三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和载脂蛋白A-I(apoA-I)的含量;HE染色观察主动脉病理形态学改变;高效液相色谱法检测主动脉壁和腹股沟皮下脂肪组织胆固醇含量:RT-PCR检测腹股沟皮下脂肪组织LXRα、ABCA1和ABCG1 mRNA的表达.结果 对照组、模型组和烟酸干预组脂肪组织胆固醇含量分别为(3.13±0.19)、(20.81±1.97)和(4.00±0.81)mg/g;相对于模型组,烟酸干预可分别上调脂肪组织胆固醇外流调控子LXRα、ABCA1和ABCG1 mRNA 144%、47.3%和73.8%,降低血清TG、TC和LDL-C而升高HDL-C和apoA-I;Pearson相关分析显示动脉壁胆固醇含量与内膜厚度/中膜厚度比值正相关(r=0.58,P＜0.05);烟酸干预组血管壁良性重塑,内膜变薄、内膜厚度/中膜厚度比值降低,内皮下间隙脂质沉积尤其是胆固醇蓄积减少.结论 烟酸干预促进了外周脂肪组织的胆固醇逆向转运,使得血液中脂质谱发生变化,进而影响了动脉壁内皮下间隙脂质尤其是胆固醇的蓄积,使血管壁发生良性重塑、动脉粥样硬化斑块消退.     

糖基化终末产物促进大鼠血管平滑肌细胞钙化

目的 观察糖基化终末产物对体外培养的血管平滑肌细胞钙化的影响.方法 在含10 mmol/Lβ-甘油磷酸钠培养液中加入不同浓度(0、50、100、200 mg/L和400 mg/L)的糖基化终末产物与大鼠血管平滑肌细胞孵育不同时间.采用磷酸苯二钠法检测碱性磷酸酶活性,甲-酚酞络合酮方法测定钙含量,实时定量逆转录聚合酶链反应检测成骨细胞特异性核心结合因子、碱性磷酸酶以及骨桥蛋白基因表达,蛋白免疫印迹检测成骨细胞特异性核心结合因子及骨桥蛋白蛋白表达.结果 与对照组相比,糖基化终末产物随作用时间延长和浓度增加,细胞钙含量增加(P<0.05),升高碱性磷酸酶活性和基因表达(P<0.05),促进成骨细胞特异性核心结合因子及骨桥蛋白基因及蛋白表达(P<0.01).结论 糖基化终末产物可促进体外培养的大鼠血管平滑肌细胞钙化.     

罗格列酮抑制糖基化终产物诱导心肌成纤维细胞增殖和结缔组织生长因子及Smad的表达

Objective To investigate the effects of rosiglitazone on the proliferation,connective tissue growth factor and Smad expression in cultured cardiac fibroblasts induced by advanced glycosylation end-products (AGEs).Methods After being treated with various amounts of rosiglitazone,the cultured neonatal rat cardiac fibroblasts were incubated with AGEs.The status of cardiac fibroblasts proliferation and cell cycle were detected by 3-(4,5-dimethyhhiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTI) assay and flow cytometry.Furthermore,ELISA technique was applied to identify the level of TGF-β1.The protein expressions of CTGF and Smad in cardiac fibroblasts of neonatal SD rats were detected with Western blotting.Results The exposure of cardiac fibroblasts to AGEs at doses of 0-200 mg/L induced a dose-dependent increase in cell proliferation.At the concentration of rosiglitazooe (0.1,1,and 10 μmol/L),the cell proliferation was reduced compared with 200 mg/L AGEs group by O.823±0.072,0.785±0.060,0.601±0.081 vs 0.981±0.049,respectively (P < 0.05).The increased levels of TGF-β1 in supematants of cultured cardiac fibroblasts stimulated by AGEs were inhibited by rosiglitazone at the concentrations of 0.1,1,10μmol/L by 257.77±9.09,230.29±6.56,200.84±10.26 vs 300.68±8.56,respectively (vs 200 mg/L AGEs,P<0.01).Western blot indicated that pretreatment with rosiglitazone (0.1,1,and 10 μmol/L) inhibited CTGF protein production in a dose-dependent by 0.769±0.108,0.590±0.095,0.534±0.115 vs 1.021±0.113,respectively (vs 200 mg/L AGEs,P<0.01).It was also demonstrated that pretreatment with rosiglitazone (1 and 10 μmol/L) inhibited Smad2 protein production by 0.424±0.059,0.396±O.080 vs 0.572±0.073,respectively (vs 200 mg/L AGEs,P < 0.05 or P < 0.01).Meanwhile pretreatment with rosiglitazone (1 and 10 μmol/L) inhibited Smad4 protein production by 0.580±0.063,0.556±0.051 vs 0.672±0.059,respectively (vs 200 mg/L AGEs,P < 0.05 or P < 0.01).Conclusions The findings suggest that AGEs promote the proliferation of cardiac fibroblasts and stimulate the protein production of Smad and CTGF of cardiac fibroblasts.Rosiglitazone inhibits the above reaction.These results indicate that CTGF/Smad pathway may play an important role in the protective effect of rosiglitazone on myocardial fibrosis.